A CME Symposium Held Adjunct with the 2026 ASCO® Annual Meeting
Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting
Meeting Room
Continental Room B (Lobby Level)
No registration fee is charged for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.
Faculty
Faculty
Paul G Richardson
MD
Dana-Farber Cancer Institute, Boston, Massachusetts
Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center
Harvard Medical School, Boston, Massachusetts
RJ Corman Professor of Medicine
Moderator
Sagar Lonial
MD, FACP, FASCO
Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia
Chair and Professor, Department of Hematology and Medical Oncology, Chief Medical Officer
Additional faculty to be announced.
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and GSK.
Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting
MODULE 1: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)
- Research database documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in patients with R/R MM
- Published data from the Phase III KarMMa-3 and CARTITUDE-4 trials of ide-cel and cilta-cel, respectively, in earlier lines of treatment; overall survival findings from CARTITUDE-4
- FDA approvals of ide-cel and cilta-cel in earlier settings; identification of patients appropriate for CAR T-cell therapy and optimal sequencing with regard to other evidence-based approaches
- Spectrum, incidence and severity of acute and long-term toxicities with BCMA-directed CAR T-cell therapy in patients with MM; appropriate monitoring and management algorithms
- Rationale for the evaluation of CAR T-cell platforms with novel targets and/or manufacturing processes for R/R MM
- Early data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel for R/R MM; FDA regenerative medicine advanced therapy designation and ongoing evaluation
- Preliminary efficacy and safety results from the Phase Ib/II DURGA-1 study of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy using the FasTCAR rapid manufacturing platform, for R/R MM; future development plans
- Preliminary data and ongoing clinical research with other novel CAR T-cell platforms for R/R MM
MODULE 2: Integrating Bispecific Antibodies into the Management of R/R MM
- Similarities and differences in the cellular targets and mechanisms of action of the various bispecific antibodies used for MM
- Efficacy and safety findings leading to the FDA approvals of the BCMA-directed bispecific antibodies teclistamab, elranatamab and linvoseltamab for heavily pretreated MM; optimal incorporation into current management algorithms
- Published and emerging Phase III findings with teclistamab, either in combination (from the MajesTEC-3 trial) or as monotherapy (from the MajesTEC-9 trial), in earlier lines of treatment; clinical implications
- Key efficacy and safety data with the GPRC5D-targeted bispecific antibody talquetamab for heavily pretreated disease; optimal selection of patients for this agent
- Biological rationale for and published findings with the FcRH5-directed bispecific antibody cevostamab in the treatment of R/R MM
- Optimal selection of patients with R/R MM for BCMA- and non-BCMA-targeted bispecific antibodies; considerations guiding the sequencing of these agents relative to other strategies and each other
- Rationale for, early data with and ongoing studies — including in the first-line setting — of bispecific antibodies in combination with other bispecific antibody platforms or standard systemic therapies for MM
- Incidence and severity of cytokine release syndrome, neurotoxicity and other adverse events (AEs) with BCMA- and non-BCMA-targeted bispecific antibodies; optimal mitigation and management strategies
- Ongoing and planned Phase III research studies with bispecific antibodies alone and in combination for MM
MODULE 3: Potential Utility of Antibody-Drug Conjugates for MM
- Mechanism of action and structural components of belantamab mafodotin
- Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM
- Key efficacy and safety data from the Phase III DREAMM-7 and DREAMM-8 trials evaluating belantamab mafodotin in combination with bortezomib/dexamethasone and with pomalidomide/dexamethasone, respectively, for patients who have received ≥1 prior line of therapy; overall survival findings from DREAMM-7
- FDA approval and current role of belantamab mafodotin-based combination strategies in the management of R/R MM
- Incidence, severity, mitigation and management of belantamab mafodotin-related adverse events (AEs), including ocular toxicities
MODULE 4: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) in Therapy for MM
- Mechanism of action of CELMoDs; similarities and differences among iberdomide, mezigdomide and standard immunomodulatory drugs (IMiDs)
- Available data documenting the efficacy and safety of iberdomide and mezigdomide as monotherapy and combined with other systemic therapies for patients with R/R MM
- Emerging findings from the Phase III EXCALIBER-RRMM study indicating an improvement in minimal residual disease negativity rates with iberdomide/daratumumab/dexamethasone compared to daratumumab/bortezomib/dexamethasone for patients with R/R MM
- Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role of CELMoDs
- Spectrum, frequency and severity of AEs observed with CELMoDs in published clinical studies; comparative tolerability profiles of iberdomide, mezigdomide and traditional IMiDs
Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.
Learning Objectives
Upon completion of this activity, participants should be able to
- Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens for patients with relapsed/refractory (R/R) multiple myeloma (MM).
- Evaluate published research findings to identify patients with R/R MM for whom treatment with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) should be considered and/or recommended.
- Assess available research data with BCMA- and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into clinical algorithms.
- Recall presented clinical research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM.
- Analyze the mechanism of action of, published and emerging efficacy and safety findings with and ongoing research evaluating cereblon E3 ligase modulators to prepare for the potential clinical availability of these agents for patients with R/R MM.
- Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly used in the care of patients with R/R MM.
- Recall available data with novel agents and strategies currently under investigation for R/R MM, and as applicable, discuss clinical trial participation with eligible patients.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.
FACULTY
To be announced.
MODERATOR
To be announced.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and GSK.
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400
Meeting Room
Continental Room B (Lobby Level)
Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.
You have successfully registered
See you on Monday, Jun 1
Format:
Chicago, IL
Date & Time:
Monday, Jun 1 7:00 PM — 9:00 PM CT
To register for this event, please log in.
Don’t have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Or
